Physiomics Plc announces changes to its board of directors. The Company announced that Dr. Peter Sargent, currently Chief Operating Officer, has been appointed as Chief Executive Officer of the Company with immediate effect. Dr. Sargent joined the Company in September 2023 as Chief Operating Officer and has quickly proved invaluable in helping to drive the Company's business development agenda, supporting the technical team and developing overall strategy.

He has worked closely with Dr. Millen over the last five months and has already taken on responsibility for many of the activities that will be at the core of his new, expanded role. Dr. Millen will remain closely involved with the Company as Non-Executive Chairman and will be available as needed to provide additional support to the executive team during the transition period and on an ongoing basis. Prior to joining Physiomics in September 2023, Dr. Sargent held a senior management role at global consultancy business Syneos Health Inc. Among his other previous roles, Dr. Sargent has also been Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.

Dr. Jim Millen has acted as Executive Chairman and Chief Executive Officer of Physiomics since February 2022, and the changes announced 22 January 2024, together with the appointment of two Non-Executive Directors in 2022, completes a restructuring of the leadership team which the Board believes provides a strong platform for the growth of the business and more closely aligns the structure of the Board with the guidelines of the QCA Corporate Governance Code.